Skip to main content
. 2026 Oct 14;3(1):e20260040. doi: 10.70962/jhi.20260040

Figure 7.

Multiple line graphs depict changes in B-cell subsets over time. Panel A: A line graph shows the mean percentage of naive B cells over time, with CD19 positive, CD27 negative, and CD10 negative markers; the y-axis ranges from 0 to 120 percent. Panel B: A line graph shows the mean percentage of transitional B cells over time, with CD19 positive, CD27 negative, and CD10 positive markers; the y-axis ranges from 0 to 60 percent. Panel C: A line graph shows the mean percentage of non-switched memory B cells over time, with CD19 positive, CD27 positive, and immunoglobulin D positive markers; the y-axis ranges from minus 10 to 40 percent. Panel D: A line graph shows the mean percentage of switched memory B cells over time, with CD19 positive, CD27 positive, and immunoglobulin D negative markers; the y-axis ranges from 0 to 60 percent. Panel E: A line graph shows the mean percentage of plasmablasts over time, with CD19 positive, CD27 positive, and CD38 strongly positive markers; the y-axis ranges from minus 15 to 30 percent. Panel F: A line graph shows mean immunoglobulin M values over time, with the y-axis ranging from 0 to 900 milligrams per deciliter. All panels compare the overall cohort, previous leniolisib, previous placebo, and new to open-label extension groups across Baseline, ED84, ED168, and ED252, with error bars showing standard deviation and gray boxes indicating reference ranges.

Sustained changes in B cell subsets. (A) Mean naïve B cell percentages (CD19+CD27−CD10−) over time. (B) Mean transitional B cell percentages (CD19+CD27−CD10+) over time. (C) Mean non-switched memory B cell percentages (CD19+CD27+IgD+) over time. (D) Mean switched memory B cell percentages (CD19+CD27+IgD−) over time. (E) Mean plasmablast percentages (CD19+CD27+CD38++) over time. (F) Mean IgM values over time. Patients are grouped into the following categories: overall (total cohort), previous leniolisib (received leniolisib prior to OLE), previous placebo (received placebo prior to OLE), and new to OLE (were not enrolled in prior leniolisib trials). Gray boxes indicate reference ranges, which were obtained from literature (panels A–E) or the clinical study report (panel F) (24). In F, for individual data that were reported as less than a certain value, the actual number was entered to graph the data. Error bars are SD.